{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:41:23Z","timestamp":1793209283193,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R50CA251708"],"award-info":[{"award-number":["1R50CA251708"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA244576"],"award-info":[{"award-number":["1R01CA244576"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009858","name":"Gabrielle\u2019s Angel Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2319-19"],"award-info":[{"award-number":["2319-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7000-18"],"award-info":[{"award-number":["7000-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aberrant B-cell receptor (BCR) signaling is a key driver in lymphoid malignancies. Bruton tyrosine kinase (BTK) inhibitors that disrupt BCR signaling have received regulatory approvals in therapy of mantle cell lymphoma (MCL). However, responses are incomplete and patients who experience BTK inhibitor therapy failure have dire outcomes. CG-806 (luxeptinib) is a dual BTK\/SYK inhibitor in clinical development in hematologic malignancies. Here we investigated the pre-clinical activity of CG-806 in MCL. In vitro treatment with CG-806 thwarted survival of MCL cell lines and patient-derived MCL cells in a dose-dependent manner. CG-806 blocked BTK and SYK activation and abrogated BCR signaling. Contrary to ibrutinib, CG-806 downmodulated the anti-apoptotic proteins Mcl-1 and Bcl-xL, abrogated survival of ibrutinib-resistant MCL cell lines, and partially reversed the pro-survival effects of stromal microenvironment-mimicking conditions in primary MCL cells. Dual BTK\/SYK inhibition led to mitochondrial membrane depolarization accompanied by mitophagy and metabolic reprogramming toward glycolysis. In vivo studies of CG-806 demonstrated improved survival in one of the two tested aggressive MCL PDX models. While suppression of the anti-apoptotic Bcl-2 family proteins and NF\u03baB signaling correlated with in vivo drug sensitivity, OxPhos and MYC transcriptional programs were upregulated in the resistant model following treatment with CG-806. <jats:italic>BAX<\/jats:italic> and <jats:italic>NFKBIA<\/jats:italic> were implicated in susceptibility to CG-806 in a whole-genome CRISPR-Cas9 library screen (in a diffuse large B-cell lymphoma cell line). A high-throughput in vitro functional drug screen demonstrated synergy between CG-806 and Bcl-2 inhibitors. In sum, dual BTK\/SYK inhibitor CG-806 disrupts BCR signaling and induces metabolic reprogramming and apoptosis in MCL. The Bcl-2 network is a key mediator of sensitivity to CG-806 and combined targeting of Bcl-2 demonstrates synergy with CG-806 warranting continued exploration in lymphoid malignancies.<\/jats:p>","DOI":"10.1038\/s41419-022-04684-1","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T19:04:00Z","timestamp":1647457440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Elana","family":"Thieme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Bruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Roleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamilla","family":"Nechiporuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Danilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bottomly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K.","family":"McWeeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"4684_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11899-021-00605-9","volume":"16","author":"E Nabrinsky","year":"2021","unstructured":"Nabrinsky E, Danilov AV, Koller PB. High-risk mantle cell lymphoma in the era of novel agents. Curr Hematol Malig Rep. 2021;16:8\u201318.","journal-title":"Curr Hematol Malig Rep."},{"key":"4684_CR2","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4:2927\u201338.","journal-title":"Blood Adv"},{"key":"4684_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, et al. Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma. Blood. 2016;128:82\u201392.","journal-title":"Blood."},{"key":"4684_CR4","doi-asserted-by":"crossref","unstructured":"Gordon M, Danilov AV. The evolving role of Bruton\u2019s tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia. Ther Adv Hematol. 2021;12:2040620721989588.","DOI":"10.1177\/2040620721989588"},{"key":"4684_CR5","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood."},{"key":"4684_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Disco. 2014;4:1022\u201335.","journal-title":"Cancer Disco"},{"key":"4684_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjh.15108","volume":"181","author":"O Hershkovitz-Rokah","year":"2018","unstructured":"Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol. 2018;181:306\u201319.","journal-title":"Br J Haematol"},{"key":"4684_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"4684_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25:119\u201329.","journal-title":"Nat Med"},{"key":"4684_CR10","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of IkappaB. Mol Cancer Ther. 2018;17:2564\u201374.","journal-title":"Mol Cancer Ther"},{"key":"4684_CR11","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1080\/10428194.2019.1616190","volume":"60","author":"S Best","year":"2019","unstructured":"Best S, Liu T, Bruss N, Kittai A, Berger A, Danilov AV. Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. Leuk Lymphoma. 2019;60:2946\u201350.","journal-title":"Leuk Lymphoma"},{"key":"4684_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"4684_CR13","first-page":"5200","volume":"130","author":"H Zhang","year":"2017","unstructured":"Zhang H, Local A, Benbatoul K, Folger P, Sheng S, Tsai C-Y. et al. CG \u2018806, a first-in-class non-covalent pan-FLT3\/BTK inhibitor, exerts superior potency against B-cell malignant cells. Blood. 2017;130(Supplement 1):5200.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4684_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141495","volume":"136","author":"R Bejar","year":"2020","unstructured":"Bejar R, Zhang H, Rastgoo N, Benbatoul K, Jin Y, Thayer M. et al. A phase 1 a\/b dose escalation study of the mutation agnostic BTK\/FLT3 inhibitor CG-806 in patients with relapsed or refractory CLL\/SLL or non-Hodgkin\u2019s lymphomas. Blood. 2020;136(Supplement 1):35.","journal-title":"Blood"},{"key":"4684_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189\u201395.","journal-title":"Nature."},{"key":"4684_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","volume":"127","author":"HM Amin","year":"2003","unstructured":"Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O\u2019Connor SL, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003;127:424\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"4684_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717\u201321.","journal-title":"Nature."},{"key":"4684_CR18","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3324\/haematol.2017.170571","volume":"102","author":"C Paiva","year":"2017","unstructured":"Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, et al. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;102:1890\u2013900.","journal-title":"Haematologica."},{"key":"4684_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koster J, DeSouza TA, et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell. 2016;29:574\u201386.","journal-title":"Cancer Cell"},{"key":"4684_CR20","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","volume":"27","author":"T Liu","year":"2021","unstructured":"Liu T, Lam V, Thieme E, Sun D, Wang X, Xu F, et al. Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner. Clin Cancer Res. 2021;27:4910\u201322.","journal-title":"Clin Cancer Res"},{"key":"4684_CR21","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1128\/MCB.20.8.2687-2695.2000","volume":"20","author":"C Chen","year":"2000","unstructured":"Chen C, Edelstein LC, Gelinas C. The Rel\/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687\u201395.","journal-title":"Mol Cell Biol"},{"key":"4684_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0157-6","volume":"9","author":"H Rauert-Wunderlich","year":"2018","unstructured":"Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NFkappaB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 2018;9:86.","journal-title":"Cell Death Dis"},{"key":"4684_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/bloodadvances.2018026880","volume":"3","author":"S Best","year":"2019","unstructured":"Best S, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, et al. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Adv. 2019;3:51\u201362.","journal-title":"Blood Adv"},{"key":"4684_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ"},{"key":"4684_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/10715761003667554","volume":"44","author":"GY Liou","year":"2010","unstructured":"Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44:479\u201396.","journal-title":"Free Radic Res"},{"key":"4684_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1158\/1535-7163.MCT-18-0766","volume":"18","author":"JT Teh","year":"2019","unstructured":"Teh JT, Zhu WL, Newgard CB, Casey PJ, Wang M. Respiratory capacity and reserve predict cell sensitivity to mitochondria inhibitors: mechanism-based markers to identify metformin-responsive cancers. Mol Cancer Ther. 2019;18:693\u2013705.","journal-title":"Mol Cancer Ther"},{"key":"4684_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41556-018-0176-2","volume":"20","author":"K Palikaras","year":"2018","unstructured":"Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol. 2018;20:1013\u201322.","journal-title":"Nat Cell Biol"},{"key":"4684_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24:1216\u201324.","journal-title":"Nat Med"},{"key":"4684_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","volume":"126","author":"TM Liu","year":"2015","unstructured":"Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126:61\u20138.","journal-title":"Blood."},{"key":"4684_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/leu.2014.263","volume":"29","author":"S Cheng","year":"2015","unstructured":"Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29:895\u2013900.","journal-title":"Leukemia."},{"key":"4684_CR31","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808\u201318.","journal-title":"Blood."},{"key":"4684_CR32","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","volume":"127","author":"K Bojarczuk","year":"2016","unstructured":"Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127:3192\u2013201.","journal-title":"Blood."},{"key":"4684_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0874-3","volume":"22","author":"L Fletcher","year":"2020","unstructured":"Fletcher L, Nabrinsky E, Liu T, Danilov A. Cell death pathways in lymphoid malignancies. Curr Oncol Rep. 2020;22:10.","journal-title":"Curr Oncol Rep."},{"key":"4684_CR34","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Trelinski J, Homenda W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93:921\u201330.","journal-title":"Am J Hematol"},{"key":"4684_CR35","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578\u201385.","journal-title":"Blood."},{"key":"4684_CR36","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3324\/haematol.2020.270298","volume":"106","author":"AS Kittai","year":"2021","unstructured":"Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, et al. Entospletinib and obinutuzumab in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell malignancies. Haematologica. 2021;106:2022\u201325.","journal-title":"Haematologica"},{"key":"4684_CR37","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","volume":"26","author":"AV Danilov","year":"2020","unstructured":"Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, et al. Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2020;26:2810\u20138.","journal-title":"Clin Cancer Res"},{"key":"4684_CR38","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41375-020-01108-x","volume":"35","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, et al. Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia. 2021;35:2108\u201313.","journal-title":"Leukemia"},{"key":"4684_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47305-2","volume":"9","author":"B Sharif-Askari","year":"2019","unstructured":"Sharif-Askari B, Doyon D, Paliouras M, Aloyz R. Bruton\u2019s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. Sci Rep. 2019;9:11069.","journal-title":"Sci Rep."},{"key":"4684_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0039-2","volume":"8","author":"G Galicia-Vazquez","year":"2018","unstructured":"Galicia-Vazquez G, Smith S, Aloyz R. Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood Cancer J. 2018;8:13.","journal-title":"Blood Cancer J"},{"key":"4684_CR41","doi-asserted-by":"publisher","first-page":"650.","DOI":"10.3390\/cancers12030650","volume":"12","author":"S Roy Chowdhury","year":"2020","unstructured":"Roy Chowdhury S, Bouchard EDJ, Saleh R, Nugent Z, Peltier C, Mejia E, et al. Mitochondrial respiration correlates with prognostic markers in chronic lymphocytic leukemia and is normalized by ibrutinib treatment. Cancers (Basel). 2020;12:650.","journal-title":"Cancers (Basel)"},{"key":"4684_CR42","doi-asserted-by":"publisher","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"4684_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fonc.2018.00411","volume":"8","author":"G Galicia-Vazquez","year":"2018","unstructured":"Galicia-Vazquez G, Aloyz R. Ibrutinib resistance is reduced by an inhibitor of fatty acid oxidation in primary CLL lymphocytes. Front Oncol. 2018;8:411.","journal-title":"Front Oncol"},{"key":"4684_CR44","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1515\/hsz-2012-0198","volume":"393","author":"BG Hill","year":"2012","unstructured":"Hill BG, Benavides GA, Lancaster JR Jr, Ballinger S, Dell\u2019Italia L, Jianhua Z, et al. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol Chem. 2012;393:1485\u2013512.","journal-title":"Biol Chem"},{"key":"4684_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A. et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369\u201384.e13.","journal-title":"Cancer Cell"},{"key":"4684_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat. Signal Transduct Target Ther. 2020;5:124.","journal-title":"Signal Transduct Target Ther"},{"key":"4684_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619\u201334.","journal-title":"Nat Rev Cancer"},{"key":"4684_CR48","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04684-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:51:06Z","timestamp":1669301466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04684-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["4684"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04684-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AVD has received consulting fees from AstraZeneca, Abbvie, BeiGene, Genentech, TG Therapeutics, Bayer Oncology, and Pharmacyclics and has ongoing research funding from AstraZeneca, Takeda Oncology, Bayer Oncology, Genentech, SecuraBio, MEI, TG Therapeutics, and Bristol Myers Squibb. JWT received research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Petra, Seattle Genetics, Syros, Takeda, and Tolero.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Experiments performed with animals compiled were approved by the Institutional Animal Care and Use Committee (IACUC) of the Oregon Health and Science University. Use of patient samples was approved by Oregon Health and Science University IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"246"}}